文献速递肺外科

Ⅳ期非小细胞肺癌挽救性手术的单中心初步经验

Initial single-institutional experience with salvage surgery for stage IV non-small-cell lung cancer.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-01-01

本研究评估临床Ⅳ期非小细胞肺癌挽救性手术的手术结局,纳入2010至2022年间接受全身治疗后肺切除的14例患者。术前全身治疗包括EGFR-TKI(8例)和非TKI药物(6例:单纯化疗4例,化疗联合免疫检查点抑制剂2例)。中位随访5.2年,EGFR-TKI组5年总生存率为83%,但无4年无复发生存者;非EGFR-TKI组5年无复发生存率为33%,2例无复发且未进一步治疗生存超过3年。

要点

  • EGFR-TKI组5年总生存率83%,但无4年无复发生存者
  • 非EGFR-TKI组5年无复发生存率33%,2例无复发生存超3年
  • 非TKI治疗后的挽救性手术可视为真正的挽救性手术

核心结论

  • 非TKI治疗(化疗联合或不联合免疫检查点抑制剂)后行挽救性手术可视为真正的挽救性手术。

研究设计与样本

  • 单中心回顾性研究,纳入2010至2022年间接受全身治疗后肺切除的临床Ⅳ期非小细胞肺癌患者14例。

主要发现

  • 中位随访5.2年,EGFR-TKI组5年总生存率为83%。
  • EGFR-TKI组无4年无复发生存者,生存获益源于复发后治疗。
  • 非EGFR-TKI组5年无复发生存率为33%,2例无复发且未进一步治疗生存超过3年。

关键数值与推荐

  • 术前全身治疗:EGFR-TKI 8例;非TKI药物6例(单纯化疗4例,化疗联合免疫检查点抑制剂2例)。

临床怎么用

  • 对初始临床Ⅳ期非小细胞肺癌,非TKI治疗后行挽救性手术可能带来无复发生存获益。

局限性

  • 单中心小样本(14例)回顾性研究,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to assess surgical outcomes of salvage surgery for clinical stage IV non-small-cell lung cancer. A total of 14 patients who underwent lung resection following systemic therapy between 2010 and 2022 were included in this study. Systemic therapy prior to surgery included agents including epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in eight patients and non-TKI agents in six (chemotherapy alone: four, chemotherapy plus immune checkpoint inhibitors: two). During a median follow-up of 5.2 years, the EGFR-TKI group showed a favourable 5-year overall survival of 83%; however, it was due to treatment after relapse, and there were no 4-year relapse-free survivors. The non-EGFR-TKI group showed a 5-year relapse-free survival of 33%, and 2 patients have survived more than 3 years without any relapse and further treatment. When considering the role of surgery in multimodal treatment for initial c-stage IV non-small-cell lung cancer, salvage surgery following non-TKI therapy (chemotherapy with or without immune checkpoint inhibitor) can be regarded as genuine salvage surgery.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Hishida T, Oka N, Yano K, et al. Initial single-institutional experience with salvage surgery for stage IV non-small-cell lung cancer. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 39951284. doi:10.1093/icvts/ivaf029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。